(Q74118693)
Statements
A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies (English)
Lissoni P
Bolis S
Brivio F
scientific article published on 01 May 2000